Literature DB >> 122160

Valproic acid-phenytoin interaction.

P N Friel, K W Leal, A J Wilensky.   

Abstract

The interaction between valproic acid (VPA) and phenytoin (DPH) was examined during therapeutic monitoring in an epileptic outpatient population. Gas-liquid chromatographic methods were used to measure DPH and VPA concentrations. (1) In 12 patients on stable DPH regimens, the mean DPH level declined from 19.7 to 15.3 microgram/ml when VPA was added (p less than 0.001). (2) In 20 patients receiving DPH and VPA, the median free fraction was 15.8%, compared to 9.1% free DPH in 40 patients receiving DPH only or DPH and phenobarbital (p less than 0.001). (3) Addition of VPA to a stable DPH regimen may result in a transient increased risk of DPH toxicity, followed by restabilization at the original free DPH level.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 122160     DOI: 10.1097/00007691-197901020-00005

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  6 in total

1.  Effect of saliva flow rate on saliva phenytoin concentrations: implications for therapeutic monitoring.

Authors:  F Kamali; S H Thomas
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 2.  Protein binding displacement interactions and their clinical importance.

Authors:  J C McElnay; P F D'Arcy
Journal:  Drugs       Date:  1983-05       Impact factor: 9.546

Review 3.  Drug interactions with phenytoin.

Authors:  E Perucca; A Richens
Journal:  Drugs       Date:  1981-02       Impact factor: 9.546

Review 4.  Pharmacokinetic interactions with antiepileptic drugs.

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

5.  Phenytoin-valproate interaction: importance of saliva monitoring in epilepsy.

Authors:  C Knott; A Hamshaw-Thomas; F Reynolds
Journal:  Br Med J (Clin Res Ed)       Date:  1982-01-02

Review 6.  Drug interactions with valproic acid.

Authors:  R H Levy; K M Koch
Journal:  Drugs       Date:  1982-12       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.